A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum

Background:  Melanoma represents only 4% of all skin cancers, but nearly 80% of skin cancer deaths. This manuscript applies several new measurement technologies with the purpose of elucidating molecular signatures of melanoma aggressiveness.

[1]  Virginia Espina,et al.  Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles , 2008, Nano research.

[2]  R. Webb,et al.  In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. , 1995, The Journal of investigative dermatology.

[3]  C. Longo,et al.  Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas. , 2005, Archives of dermatology.

[4]  W. Schempp,et al.  Molecular diagnosis in dermatopathology: What makes sense, and what doesn’t , 2009, Experimental dermatology.

[5]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[7]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[8]  J. Hansson,et al.  Cisplatin Induces the Proapoptotic Conformation of Bak in a ΔMEKK1-Dependent Manner , 2001, Molecular and Cellular Biology.

[9]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[10]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[11]  C. Dive,et al.  Mitochondrial membrane permeabilisation by Bax/Bak. , 2003, Biochemical and biophysical research communications.

[12]  G. Tchernev,et al.  Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl‐2‐related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings , 2007, Journal of cutaneous pathology.

[13]  H. Antoniades,et al.  Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo , 1996, The British journal of dermatology.

[14]  C. Longo,et al.  The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions. , 2007, The Journal of investigative dermatology.

[15]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Eberle,et al.  CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants , 2003, Oncogene.

[17]  S. Seidenari,et al.  Reflectance-mode confocal microscopy for the in vivo characterization of pagetoid melanocytosis in melanomas and nevi. , 2005, The Journal of investigative dermatology.

[18]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[19]  E. Petricoin,et al.  Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. , 2009, Journal of materials chemistry.

[20]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[21]  Weidong Zhou,et al.  Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers , 2009, PloS one.

[22]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[23]  J. Eberle,et al.  Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. , 2006, The Journal of investigative dermatology.

[24]  Giovanni Pellacani,et al.  In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. , 2009, The Journal of investigative dermatology.

[25]  V. Sondak,et al.  Markers and tissue resources for melanoma: meeting report. , 2006, Cancer research.

[26]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[27]  Emanuel F. Petricoin,et al.  Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer , 2008, Molecular & Cellular Proteomics.

[28]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[29]  J. Utikal,et al.  Tumor biomarkers in melanoma. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[30]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[31]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[32]  C. Belka,et al.  Guardians of cell death: the Bcl-2 family proteins. , 2003, Essays in biochemistry.

[33]  M. Vinceti,et al.  Melanoma epidemic across the millennium: time trends of cutaneous melanoma in Emilia‐Romagna (Italy) from 1997 to 2004 , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[34]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[35]  Virginia Espina,et al.  Protein microarrays: Molecular profiling technologies for clinical specimens , 2003, Proteomics.